Alkaloid

Alkaloid is a pharmaceutical and chemicals company headquartered in Skopje, North Macedonia. Established in 1936, it has operated for more than eight decades in the manufacture of medicines, cosmetic products and chemical products, as well as in the processing of botanical raw materials. The company uses Alkaloid AD Skopje as its legal corporate identity and operates both as a manufacturer and as a portfolio brand across healthcare and related product categories. Its business is organized around two principal profit centers. The Pharmaceuticals center covers the company’s medicine-related activities, while the Chemicals, Cosmetics and Botanicals center encompasses chemical products, personal-care products and the processing of plant-based raw materials. This structure gives Alkaloid a broader scope than a single-product pharmaceutical label, combining prescription and non-prescription healthcare activities with consumer and industrial-related operations. Alkaloid’s corporate development included a change in ownership structure during the 1990s. In 1990, the enterprise was transformed into a joint-stock company with participation by the state treasury. In 1998, it became a fully privatized joint-stock company. The company is listed on the North Macedonian capital market under the ticker ALK. The group maintains operations beyond North Macedonia through domestic subsidiaries and an international network of subsidiaries and representative offices. The cited company description identifies two subsidiaries in North Macedonia, together with 16 subsidiaries and three representative offices abroad. Its listed international presence includes markets in the Balkans and wider Europe, as well as Turkey, Ukraine, Russia and the United States. The same reference reports 1,580 employees in North Macedonia and a further 420 employees in foreign subsidiaries and representative offices; these figures are presented as reference-period staffing data rather than as a current estimate. Alkaloid’s principal positioning is that of an integrated regional pharmaceutical and healthcare-products manufacturer with adjacent capabilities in cosmetics, chemicals and botanical processing. Publicly available material supplied for this dossier does not establish a complete current product catalogue, detailed therapeutic-area ranking, revenue breakdown, current executive roster or precise market-by-market sales performance. Those details are therefore not inferred here.

Alkaloid traces its origins to 1936 in Skopje, where it developed over the following decades as a manufacturer serving the pharmaceutical and related chemical industries. Its historical scope was not limited to medicines: the company also developed activities in cosmetics, chemical products and the processing of botanical raw materials. This combination formed the basis for its later organization into separate business centers covering pharmaceuticals and the combined chemicals, cosmetics and botanicals activities. A major institutional change took place in the 1990s. In 1990, Alkaloid was converted into a joint-stock company with participation by the state treasury. The ownership transformation continued during the decade, and in 1998 the company became a fully privatized joint-stock company. This transition placed Alkaloid within the market-oriented corporate and capital-market framework that followed the restructuring of the Macedonian economy. Following its transformation, Alkaloid continued developing as a diversified pharmaceutical company rather than narrowing its activities to one therapeutic or consumer category. Its portfolio has been described as including medicines, cosmetic products and chemical products, while botanical raw-material processing remains part of its operating scope. The company’s corporate name is also used as a group and market identity across these areas. The company expanded its commercial and organizational reach outside North Macedonia through subsidiaries and representative offices. The referenced company description identifies two subsidiaries in the domestic market, 16 foreign subsidiaries and three foreign representative offices. The cited network covers Serbia, Montenegro, Kosovo, Albania, Bosnia and Herzegovina, Croatia, Slovenia, Switzerland, Bulgaria, Turkey, Ukraine, Russia and the United States. This international footprint places Alkaloid among the regionally active pharmaceutical manufacturers originating in North Macedonia. Alkaloid is traded on the North Macedonian capital market under the symbol ALK. The supplied reference also reports 1,580 employees in North Macedonia and 420 employees working in overseas subsidiaries and representative offices. Because no date is supplied for those staffing figures, they should be treated as historical reference data rather than a verified current headcount. The available material does not provide a sufficiently detailed chronology of individual product introductions, manufacturing-site expansions, acquisitions, research milestones or changes in senior leadership. Accordingly, the documented history is strongest on the company’s founding, ownership transformation, business structure and international presence, while finer-grained corporate developments remain open for further research.

• 1998

  Full privatization

  [1]Alkaloid (company)en.wikipedia.org

  Alkaloid became a fully privatized joint-stock company.

• 1990

  Conversion into a joint-stock company

  [1]Alkaloid (company)en.wikipedia.org

  The company was transformed into a joint-stock company with participation by the state treasury.

• 1936

  Company established in Skopje

  [1]Alkaloid (company)en.wikipedia.org

  Alkaloid traces its origins to the establishment of the pharmaceutical enterprise in Skopje.

Integrated North Macedonian pharmaceutical, healthcare, cosmetics, chemicals and botanical-products manufacturer

• Pharmaceuticals

  Prescription medicines

  Prescription medicines are the central category within Alkaloid’s Pharmaceuticals profit center. They represent the company’s role as a healthcare manufacturer serving professional medical and pharmacy channels. The supplied sources confirm the category but do not provide a reliable complete list of products, therapeutic areas or leading brands.

• Consumer healthcare

  Over-the-counter medicines

  Alkaloid’s healthcare portfolio includes non-prescription medicines intended for pharmacy retail and consumer self-care. The available reference material supports the existence of this broad medicines activity but does not establish a full catalogue, launch chronology or market ranking for individual products.

• Cosmetics and personal care

  Cosmetic products

  Cosmetic products form part of Alkaloid’s non-pharmaceutical business alongside chemicals and botanical activities. This category extends the company’s manufacturing and brand presence into personal care and related consumer markets. Specific product families are not listed because the supplied sources do not document them in sufficient detail.

• Chemicals

  Chemical products

  Chemical products are included in Alkaloid’s operating scope and are grouped with cosmetics and botanicals in one of its two profit centers. They represent an adjacent industrial and manufacturing capability connected to the company’s wider healthcare and materials activities. The exact product range and applications are not specified in the supplied references.

• Botanical processing

  Botanical raw materials

  Alkaloid also processes botanical raw materials, an activity that distinguishes its business scope from a medicines-only manufacturer. The botanical operation is associated with the company’s Chemicals, Cosmetics and Botanicals profit center. Available sources do not provide enough detail to identify particular plants, ingredients or finished-product lines.

• 1998

  Completion of privatizationStrategy

  Background

  Alkaloid continued the ownership restructuring begun with its 1990 conversion into a joint-stock company.

  Action taken

  The company became a fully privatized joint-stock company.

  Aftermath

  Alkaloid continued as a private listed pharmaceutical and related-products company.

  Source

• 1990

  Conversion to a joint-stock structureStrategy

  Background

  During the economic and institutional changes of the 1990s, Alkaloid’s ownership and corporate form were reorganized.

  Action taken

  The company was converted into a joint-stock company with participation by the state treasury.

  Aftermath

  The change preceded the company’s full privatization later in the decade and its subsequent operation as a listed joint-stock company.

  Source

1. 1Alkaloid (company)en.wikipedia.org
2. 2Alkaloid official websitealkaloid.com.mk